SPR Therapeutics LOGO 361 TM.jpg
SPR Therapeutics’ SPRINT Peripheral Nerve Stimulation System Significantly Reduces Opioid Use in Patients with Low Back Pain, Interim Data Show
August 21, 2019 08:30 ET | SPR Therapeutics, Inc.
CLEVELAND, Ohio and KISSIMMEE, Florida, Aug. 21, 2019 (GLOBE NEWSWIRE) -- SPR Therapeutics, Inc., a leader in neurostimulation technology for pain management, presented interim results today on the...
SPRINT PNS MicroLead
Study of SPR Therapeutics’ Peripheral Nerve Stimulation System Demonstrates Significant and Sustained Relief of Post-Amputation Pain
April 08, 2019 13:39 ET | SPR Therapeutics, Inc.
CLEVELAND, April 08, 2019 (GLOBE NEWSWIRE) -- SPR Therapeutics, Inc., a leader in neurostimulation technology for pain management, today announced the results of a study of its SPRINT® Peripheral...
Peter Staats, MD, MBA
SPR Therapeutics Names Dr. Peter Staats as Chief Medical Advisor
January 15, 2019 10:00 ET | SPR Therapeutics, Inc.
CLEVELAND, Jan. 15, 2019 (GLOBE NEWSWIRE) -- SPR Therapeutics, Inc., a leader in neurostimulation technology for pain management, today announced that Peter Staats, MD, MBA, has been named Chief...
SPR Therapeutics LOGO 361 TM.jpg
SPR Therapeutics Announces First Use of SPRINT endura Peripheral Nerve Stimulation System to treat Complex Regional Pain Syndrome
November 15, 2018 08:00 ET | SPR Therapeutics, Inc.
SPRINT System is the least invasive PNS device for CRPS CLEVELAND, Nov. 15, 2018 (GLOBE NEWSWIRE) -- SPR Therapeutics, Inc., a leader in neurostimulation technology for pain management, today...
SPRINT® MicroLead
SPR Therapeutics Awarded $10M From U.S. Department of Defense
October 02, 2018 10:30 ET | SPR Therapeutics, Inc.
CLEVELAND, Oct. 02, 2018 (GLOBE NEWSWIRE) -- SPR Therapeutics, Inc., a leader in neurostimulation technology for pain management, has been awarded two new grants and one new contract from the U.S....
SPRlogo.jpg
SPR Therapeutics Announces First Use of SPRINT extensa Dual-lead Peripheral Nerve Stimulation System to Treat Low Back Pain
September 25, 2018 10:10 ET | SPR Therapeutics, Inc.
CLEVELAND, Sept. 25, 2018 (GLOBE NEWSWIRE) -- SPR Therapeutics, Inc., a leader in neurostimulation technology for pain management, today announced that Christopher Gilmore, MD of Carolinas Pain...
SPRINT® MicroLead
FDA Clears SPR Therapeutics’ Non-opioid SPRINT endura and extensa Peripheral Nerve Stimulation Systems for Pain Management
August 16, 2018 08:30 ET | SPR Therapeutics, Inc.
SPRINT® is the First and Only Dual Lead Capable PNS Platform Company also provides first look at 12-month durability outcomes following 60-day SPRINT therapy CLEVELAND, Aug. 16, 2018 (GLOBE...
SPR Therapeutics LOGO 361 TM.jpg
SPR Therapeutics® Secures $25 Million in Series C Financing
September 12, 2017 08:03 ET | SPR Therapeutics, LLC
CLEVELAND, Sept. 12, 2017 (GLOBE NEWSWIRE) -- SPR Therapeutics, Inc., (SPR) a private medical device company that has developed a novel neurostimulation technology for chronic and acute pain,...
SPR Therapeutics LOGO 361 TM.jpg
SPR Therapeutics Promotes Dr. Joseph Boggs to SVP of Research and Development
September 07, 2017 09:13 ET | SPR Therapeutics, LLC
CLEVELAND, Sept. 07, 2017 (GLOBE NEWSWIRE) -- SPR® Therapeutics, LLC (SPR), a private medical device company that has developed a novel, evidence-based neurostimulation platform for chronic and...
SPR Therapeutics LOGO 361 TM.jpg
Opioid Concerns and Work Interference Cited as Top Reasons to Delay Knee Replacement Surgery
August 03, 2017 11:03 ET | SPR Therapeutics, LLC
CLEVELAND, Ohio, Aug. 03, 2017 (GLOBE NEWSWIRE) -- Patients in need of a total knee replacement (TKR) often delay surgery by two or more years because of concerns about the duration of postoperative...